Patrick Y. Wen

Boston University — United States

Medicine · Health Sciences

145h-index86.3kcitations1.9kworks5.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(1344), Brain Metastases and Treatment(311), Cancer, Hypoxia, and Metabolism(289), Radiomics and Machine Learning in Medical Imaging(232), Neuroblastoma Research and Treatments(138)

Publications1.9k total

Prognostic significance of O6-methylguanine-DNA methyltransferase promoter methylation status in isocitrate dehydrogenase-mutant glioma
Neuro-Oncology·2025
Evaluation of sex differences in survival among glioblastoma patients treated with immune checkpoint inhibitors
Neuro-Oncology Advances·2025Open Access
Focused Ultrasound in Brain Tumors: Mechanisms, Imaging Guidance, and Emerging Clinical Applications
American Journal of Neuroradiology·2025· 1 citedOpen Access
STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma
Journal of Clinical Oncology·2025Open Access
10205-CB-7 Preclinical and clinical assessment of salvage chemoradiation after mutant IDH inhibitor treatment in glioma
Neuro-Oncology Advances·2025Open Access
10197-CS-19 A global, randomized, double-blinded, Phase 3 study of Vorasidenib versus placebo in patients with adult-type diffuse glioma with an IDH1/2 mutation (INDIGO): updated data from the Japan subgroup analysis
Neuro-Oncology Advances·2025Open Access
10204-CS-21 Exploratory analyses from the INDIGO study on the mechanism of seizure control by vorasidenib through tumor volume reduction
Neuro-Oncology Advances·2025Open Access
10001-NT-1 ACTION: A randomized phase 3 study of dordaviprone (ONC201) in patients with newly diagnosed H3 K27M-mutant diffuse glioma
Neuro-Oncology Advances·2025Open Access
Supplementary Data 1 from Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma
2025Open Access
Supplementary Figure 4 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
2025Open Access
Supplemental Figure S1 from Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma
2025Open Access
Supplementary Tables 1-8 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
2025Open Access
Supplementary Figure 6 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
2025Open Access
Supplementary Figure 3 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
2025Open Access
Supplementary Data 1 from Bavituximab Decreases Immunosuppressive Myeloid-Derived Suppressor Cells in Newly Diagnosed Glioblastoma Patients
2025Open Access
Supplementary Figure 5 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
2025Open Access
Supplementary Figure 2 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
2025Open Access
Supplemental Figure S2 from Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma
2025Open Access
Supplementary Figure 1 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
2025Open Access
A Clinical Tool to Identify Incidental Meningioma for Early Outpatient Management
JAMA Oncology·2025Open Access
page 1 of 96Next →

Frequent Co-authors

Timothy F. Cloughesy(15), David A. Reardon(10), Martin J. van den Bent(9), Minesh P. Mehta(9), Mark R. Gilbert(8), Michael D. Prados(8), Eudocia Q. Lee(8), Wolfgang Wick(7), Susan M. Chang(7), Michael Weller(7), David Schiff(6), Tracy T. Batchelor(6), Jay S. Loeffler(6), Ingo K. Mellinghoff(6), H. Ian Robins(6), Kathleen R. Lamborn(5), Michael A. Vogelbaum(5), Keith L. Ligon(5), Benjamin M. Ellingson(5), Brian M. Alexander(5)